FDA Advisers Narrowly Vote in Favor of Experimental Gene Therapy for Rare Muscle Disease

The FDA’s decision, expected by the end of the month, will have implications for how the agency regulates treatments like this one more broadly. It would be the first of its kind of medicine to get accelerated approval.